DDInter1078 DDInter1544
Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space.
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Lisdexamfetamine {u} (Compound) resembles {v} (Compound) Lacosamide
Lisdexamfetamine {u} (Compound) resembles {v} (Compound) Amphetamine
Lisdexamfetamine {u} (Compound) binds {v} (Gene) SLC6A3
Lisdexamfetamine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Lisdexamfetamine {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Lisdexamfetamine {u} (Compound) causes {v} (Side Effect) Psychotic disorder
Lisdexamfetamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ammonium chloride
Lisdexamfetamine {u} may lead to a major life threatening interaction when taken with {v} Arsenic trioxide
Lisdexamfetamine (Compound) resembles Lacosamide (Compound)
Lisdexamfetamine (Compound) resembles Amphetamine (Compound)
Lisdexamfetamine (Compound) binds SLC6A3 (Gene)
Lisdexamfetamine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Lisdexamfetamine (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Lisdexamfetamine (Compound) causes Psychotic disorder (Side Effect)
Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ammonium chloride
Lisdexamfetamine may lead to a major life threatening interaction when taken with Arsenic trioxide